CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

Word spread quickly online about the change after Caremark ... s employer clients paid for obesity drugs by 10 to 15 percent compared with the previous year. “CVS Caremark was able to do what ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

CVS Caremark announced a partnership with Novo Nordisk (NYSE:NVO) to expand access to Wegovy, a GLP-1 drug for obesity, at a ...

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...

This week, CVS Health said Wegovy will become the preferred option on its standard formulary, or list of covered drugs, as of ...